{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:43:53Z","timestamp":1787240633525,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s13402-024-01015-8","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:32:28Z","timestamp":1732527148000},"page":"2265-2276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study"],"prefix":"10.1007","volume":"47","author":[{"given":"Ruirui","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenrui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"issue":"3","key":"1015_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"H. Sung et al., Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209\u2013249 (2021)","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"1015_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"F. Bray et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394\u2013424 (2018)","journal-title":"CA Cancer J. Clin."},{"issue":"10360","key":"1015_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"A. Vogel et al., Hepatocellular carcinoma. Lancet. 400(10360), 1345\u20131362 (2022)","journal-title":"Lancet"},{"issue":"10204","key":"1015_CR4","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"M. Zhou et al., Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 394(10204), 1145\u20131158 (2019)","journal-title":"Lancet"},{"issue":"36","key":"1015_CR5","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.20.02672","volume":"38","author":"JD Gordan","year":"2020","unstructured":"J.D. Gordan et al., Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J. Clin. Oncol. 38(36), 4317\u20134345 (2020)","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 4","key":"1015_CR6","doi-asserted-by":"publisher","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","volume":"29","author":"A Vogel","year":"2018","unstructured":"A. Vogel et al., Hepatocellular carcinoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29(Suppl 4), iv238\u2013iv255 (2018)","journal-title":"Ann. Oncol."},{"issue":"4","key":"1015_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","volume":"9","author":"DY Xie","year":"2020","unstructured":"D.Y. Xie et al., 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg. Nutr. 9(4), 452\u2013463 (2020)","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"1","key":"1015_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41571-021-00577-y","volume":"19","author":"P Sidaway","year":"2022","unstructured":"P. Sidaway, FOLFOX-HAIC active in large HCC. Nat. Rev. Clin. Oncol. 19(1), 5 (2022)","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"1015_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/SLA.0000000000005434","volume":"276","author":"JM Sharib","year":"2022","unstructured":"J.M. Sharib et al., Hepatic artery infusion pumps: a Surgical Toolkit for intraoperative decision-making and management of hepatic artery infusion-specific complications. Ann. Surg. 276(6), 943\u2013956 (2022)","journal-title":"Ann. Surg."},{"issue":"5","key":"1015_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.21.01963","volume":"40","author":"N Lyu","year":"2022","unstructured":"N. Lyu et al., Arterial chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J. Clin. Oncol. 40(5), 468\u2013480 (2022)","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"1015_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"N Lyu","year":"2018","unstructured":"N. Lyu et al., Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 69(1), 60\u201369 (2018)","journal-title":"J. Hepatol."},{"issue":"2","key":"1015_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Q.J. Li et al., Hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for large Hepatocellular Carcinoma: a Randomized Phase III Trial. J. Clin. Oncol. 40(2), 150\u2013160 (2022)","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"1015_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"M. He et al., Sorafenib Plus hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: a Randomized Clinical Trial. JAMA Oncol. 5(7), 953\u2013960 (2019)","journal-title":"JAMA Oncol."},{"issue":"1","key":"1015_CR14","doi-asserted-by":"publisher","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Y. Zhao et al., Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim. et Biophys. acta Reviews cancer. 1874(1), 188391 (2020)","journal-title":"Biochim. et Biophys. acta Reviews cancer"},{"issue":"3","key":"1015_CR15","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","volume":"162","author":"GL Su","year":"2022","unstructured":"G.L. Su et al., AGA Clinical Practice Guideline on systemic therapy for Hepatocellular Carcinoma. Gastroenterology. 162(3), 920\u2013934 (2022)","journal-title":"Gastroenterology"},{"issue":"9","key":"1015_CR16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","volume":"20","author":"M Friedlander","year":"2019","unstructured":"M. Friedlander et al., Pamiparib in combination with tislelizumab in patients with advanced solid tumors: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial. Lancet Oncol. 20(9), 1306\u20131315 (2019)","journal-title":"Lancet Oncol."},{"key":"1015_CR17","doi-asserted-by":"crossref","unstructured":"Z. Ren et al., Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer 12(1), 72\u201384 (2022)","DOI":"10.1159\/000527175"},{"issue":"16","key":"1015_CR18","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2217\/fon-2019-0097","volume":"15","author":"S Qin","year":"2019","unstructured":"S. Qin et al., RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 15(16), 1811\u20131822 (2019)","journal-title":"Future Oncol."},{"key":"1015_CR19","doi-asserted-by":"publisher","first-page":"175883592110027","DOI":"10.1177\/17588359211002720","volume":"13","author":"MK He","year":"2021","unstructured":"M.K. He et al., Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther. Adv. Med. Oncol. 13, 17588359211002720 (2021)","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"4","key":"1015_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00535-023-01976-x","volume":"58","author":"Y Fu","year":"2023","unstructured":"Y. Fu et al., Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J. Gastroenterol. 58(4), 413\u2013424 (2023)","journal-title":"J. Gastroenterol."},{"key":"1015_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2022.07.005","volume":"174","author":"Z Lai","year":"2022","unstructured":"Z. Lai et al., Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial. Eur. J. Cancer. 174, 68\u201377 (2022)","journal-title":"Eur. J. Cancer"},{"key":"1015_CR22","unstructured":"J. Zhou et al., Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 9(6), 682\u2013720 (2020)"},{"issue":"1","key":"1015_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"W.M. Liu et al., Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br. J. Cancer. 102(1), 115\u2013123 (2010)","journal-title":"Br. J. Cancer"},{"issue":"2","key":"1015_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"J.M. Llovet, R. Lencioni, mRECIST for HCC: performance and novel refinements. J. Hepatol. 72(2), 288\u2013306 (2020)","journal-title":"J. Hepatol."},{"issue":"2","key":"1015_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228\u2013247 (2009)","journal-title":"Eur. J. Cancer"},{"issue":"20","key":"1015_CR26","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"R.S. Finn et al., Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl. J. Med. 382(20), 1894\u20131905 (2020)","journal-title":"N Engl. J. Med."},{"issue":"10126","key":"1015_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"M. Kudo et al., Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 391(10126), 1163\u20131173 (2018)","journal-title":"Lancet"},{"issue":"4","key":"1015_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"J.M. Llovet et al., Sorafenib in advanced hepatocellular carcinoma. N Engl. J. Med. 359(4), 378\u2013390 (2008)","journal-title":"N Engl. J. Med."},{"key":"1015_CR29","doi-asserted-by":"publisher","first-page":"929141","DOI":"10.3389\/fimmu.2022.929141","volume":"13","author":"Y Xin","year":"2022","unstructured":"Y. Xin et al., Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front. Immunol. 13, 929141 (2022)","journal-title":"Front. Immunol."},{"issue":"5","key":"1015_CR30","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Y. Yuan et al., TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int. J. Surg. 109(5), 1222\u20131230 (2023)","journal-title":"Int. J. Surg."},{"issue":"2","key":"1015_CR31","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Y. Kato et al., Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8\u2009+\u2009T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 14(2), e0212513 (2019)","journal-title":"PLoS One"},{"issue":"4","key":"1015_CR32","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/hep.30889","volume":"71","author":"K Shigeta","year":"2020","unstructured":"K. Shigeta et al., Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 Blockade promotes vascular normalization and enhances Antitumor immune responses in hepatocellular carcinoma. Hepatology. 71(4), 1247\u20131261 (2020)","journal-title":"Hepatology"},{"issue":"24","key":"1015_CR33","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.1158\/0008-5472.CAN-12-1340","volume":"72","author":"EV Malofeeva","year":"2012","unstructured":"E.V. Malofeeva et al., Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 72(24), 6457\u20136467 (2012)","journal-title":"Cancer Res."},{"key":"1015_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2147\/JHC.S417550","volume":"10","author":"S Chen","year":"2023","unstructured":"S. Chen et al., Hepatic arterial infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or without transhepatic arterial embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and high Tumor Burden: a Multicenter Retrospective Study. J. Hepatocell Carcinoma. 10, 1209\u20131222 (2023)","journal-title":"J. Hepatocell Carcinoma"}],"updated-by":[{"DOI":"10.1007\/s13402-024-01031-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000}}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-01015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-024-01015-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-024-01015-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T16:19:05Z","timestamp":1736266745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-024-01015-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s13402-024-01015-8","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"9 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article was revised: In this article the title of Figure 4 \u2018The OS in patients with different tumor diameters\u2019 should have been \u2018The OS in patients with different tumor numbers\u2019. The original article has been corrected.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13402-024-01031-8","URL":"https:\/\/doi.org\/10.1007\/s13402-024-01031-8","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study had been ethically approved by the Ethics Review Committee of the First Affiliated Hospital of Chongqing Medical University (Approval number: 2023 Research Ethics (K2023-547)) and was based on the principles of the Helsinki Declaration. Written informed consent was obtained from all individuals included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}